“Digalen a sheet anchor in pneumonia; a strong support to the heart in this deadliest of infectious diseases among adults. The prompt action of Digalen, by intravenous or intramuscular injection makes it possible to save lives which might be otherwise hopelessly lost. The best digitalis preparation which we have at the present time.”[39] [39] Advertisement in Am. Med., January and February, 1913. “_The_ digitalis for children. Because its dosage can be controlled. Endorsed by pediatrists everywhere.”[40] [40] Advertisement in Merck’s Arch., April, 1913. “The myocarditis of Tuberculosis so frequently encountered, especially in the advanced stage of the disease, may be controlled with the aid of Digalen. The standard digitalis preparation.”[41] [41] South. Medical Journal, January to May, 1913, inclusive. “Digalen is Absolutely _Reliable_. It is _standardized_ and consequently _always uniform_. It _does not produce gastric disturbances._”[42] [42] Advertisement in Brit. Med. Jour., April 26, 1913. Digalen is not a sheet anchor in pneumonia, for there is no drug deserving such a title. Digalen has no action which other digitalis preparations lack, and cannot save lives otherwise hopelessly lost. The dosage of Digalen cannot be controlled any better than that of other digitalis preparations, since its activity is variable. We cannot control the myocarditis of advanced tuberculosis by this or any other means. CLAIMED SUPERIORITY Various digitalis principles, including digitoxin, digitalin (true) and digitalein, have been known for many years. Therapeutically they have been found wanting and there appears to be no basis for the continued claim that Digalen has any superiority over these several digitalis principles. On the contrary, the evidence is accumulating that Digalen has no advantage in any particular over a solution of digitalein, and misleading claims of the manufacturers and their agents certainly interfere with the formation of that calm and unbiased opinion on the part of the general practitioner, which, when applied to the non-proprietary digitalis principles has caused them to fall into disuse.--(_From The Journal A. M. A., Sept. 5, 1914._) DIORADIN REFUSED RECOGNITION Report of the Council on Pharmacy and Chemistry A preparation called Dioradin was placed on the market as a cure for consumption three years ago in Europe and somewhat later in this country. It was first submitted to the Council in July, 1911. Because of the manifestly unwarranted claims made for its use in the treatment of tuberculosis, the Council voted that the product be refused recognition for conflict with Rule 8, without at that time taking under consideration the question whether or not it was in conflict with other rules of the Council.